Angiogenesis has emerged as a novel target for anti-cancer therapies through randomized clinical trials that tested the benefit of adding vascular endothelial growth factor (VEGF) inhibitors to conventional cytotoxic therapies. However, despite improvements in the progression-free survival, the benefit in overall survival is modest. Tumour angiogenesis is regulated by a number of angiogenic cytokines. Thus innate or acquired resistance to VEGF inhibitors can be caused, at least in part, through expression of other angiogenic cytokines, including fibroblast growth factor 2 (FGF2), interleukin 8 (IL-8) and stromal-cell-derived factor 1α (SDF-1α), which make tumours insensitive to VEGF signalling pathway inhibition. The majority of angiogenic cytokines, including VEGF-A, FGF2, IL-8 and SDF-1α, manifest an obligate dependence on heparan sulfate (HS) for their biological activity. This mandatory requirement of angiogenic cytokines for HS identifies HS as a potential target for novel anti-angiogenic therapy. Targeting multiple angiogenic cytokines with HS mimetics may represent an opportunity to inhibit tumour angiogenesis more efficiently. Our published studies and unpublished work have demonstrated the feasibility of generating synthetic HS fragments of defined structure with biological activity against a number of angiogenic cytokines.
Skip Nav Destination
Article navigation
December 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 17 2014
The development of anti-angiogenic heparan sulfate oligosaccharides
Gordon C. Jayson;
Gordon C. Jayson
1
*Institute of Cancer Sciences, Christie Hospital and University of Manchester, Withington, Manchester M20 4BX, U.K.
1To whom correspondence should be addressed (emailGordon.Jayson@ics.manchester.ac.uk).
Search for other works by this author on:
Gavin J. Miller;
Gavin J. Miller
†Manchester Institute of Biotechnology and School of Chemistry, University of Manchester, MIB, Princess Street, Manchester M1 7DN, U.K.
Search for other works by this author on:
Steen U. Hansen;
Steen U. Hansen
†Manchester Institute of Biotechnology and School of Chemistry, University of Manchester, MIB, Princess Street, Manchester M1 7DN, U.K.
Search for other works by this author on:
Marek Barath;
Marek Barath
‡Institute of Chemistry, Centre of Glycomics, Dubravska Cesta 9, 845 38 Bratislava, Slovakia
Search for other works by this author on:
John M. Gardiner;
John M. Gardiner
†Manchester Institute of Biotechnology and School of Chemistry, University of Manchester, MIB, Princess Street, Manchester M1 7DN, U.K.
Search for other works by this author on:
Egle Avizienyte
Egle Avizienyte
*Institute of Cancer Sciences, Christie Hospital and University of Manchester, Withington, Manchester M20 4BX, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
September 05 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (6): 1596–1600.
Article history
Received:
September 05 2014
Citation
Gordon C. Jayson, Gavin J. Miller, Steen U. Hansen, Marek Barath, John M. Gardiner, Egle Avizienyte; The development of anti-angiogenic heparan sulfate oligosaccharides. Biochem Soc Trans 1 December 2014; 42 (6): 1596–1600. doi: https://doi.org/10.1042/BST20140229
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.